Difficulty moving your jaw could signal certain disorders and even cancer, dentist warns
Popping and clicking sounds when you open your mouth could also indicate a problem. (Source: Daily Express - Health)
Source: Daily Express - Health - January 18, 2023 Category: Consumer Health News Source Type: news
The popular drink that could increase mouth cancer risk - labelled 'carcinogenic' by NHS
There are multiple risk factors for developing mouth cancer, including what you drink. (Source: Daily Express - Health)
Source: Daily Express - Health - January 11, 2023 Category: Consumer Health News Source Type: news
What to Know About Infusion Therapy for IBD
The human gastrointestinal tract can be a hostile place for visitors. It’s filled with digestive acids and microorganisms that rapidly break down swallowed bits of food, and it can be just as rough on non-food molecules. That includes some of the latest drugs for the treatment of inflammatory bowel disease (IBD). “Some medications that target the immune system don’t work if they’re swallowed because your gut would digest them like a piece of steak,” says Dr. Gilaad Kaplan, a gastroenterologist, IBD researcher, and professor of medicine at the University of Calgary in Canada. “You have to...
Source: TIME: Health - January 10, 2023 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized Source Type: news
‘Painful’ ulcers that do not heal can signal cancer, says doctor - regularly check mouth
Unusual lumps in the mouth and loose teeth are also signs that should be investigated, the doctor said. (Source: Daily Express - Health)
Source: Daily Express - Health - January 7, 2023 Category: Consumer Health News Source Type: news
DOACs vs Heparin in Cancer-Associated Thrombosis DOACs vs Heparin in Cancer-Associated Thrombosis
As compared with low-molecular-weight heparin, direct oral anticoagulants (DOACs) were more clinically effective and more cost-effective for treating cancer-associated thrombosis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 4, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Neoadjuvant Immunochemotherapy Promising in Oral SCC Neoadjuvant Immunochemotherapy Promising in Oral SCC
A small trial reported a 60% response rate to neoadjuvant immunochemotherapy in oral squamous cell carcinoma. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 29, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
How to Talk About HPV, Oral Sex, and Cancer With Patients How to Talk About HPV, Oral Sex, and Cancer With Patients
In the absence of clear indications from scientific authorities about how to broach the subject, clinicians must weigh the ethical implications of counseling.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - December 28, 2022 Category: Allergy & Immunology Tags: Infectious Diseases News Source Type: news
Network Meta-Analysis Compares DOACs to LMWH for Cancer-Linked Thrombosis
TUESDAY, Dec. 27, 2022 -- Direct oral anticoagulants (DOACs) are more effective and cost-effective than low-molecular-weight heparin for cancer-associated thrombosis (CAT), with the results sensitive to monthly drug costs, according to research... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 27, 2022 Category: Pharmaceuticals Source Type: news
Walnuts Slash Cancer Risk
A new study out of Marshall University found that eating two ounces of walnuts a day for two weeks slowed breast cancer growth or reduced the risk of developing the disease.1
In the study, researchers gave a group of women who had a breast biopsy two ounces of walnuts every day until they had surgery two weeks later.
They found significant changes in the tumor’s gene expression in the women who ate the nuts compared to those who didn’t.
This backs up earlier research which found that eating two ounces of walnuts a day could help cut breast cancer risk in half.2
Extracts of walnuts stopped the spread of breast cancer ce...
Source: Al Sears, MD Natural Remedies - December 23, 2022 Category: Complementary Medicine Authors: Jacob Tags: Anti-Aging Cancer Health Source Type: news
Adagrasib Shows Anti-Tumor Activity in Heavily Pretreated KRAS-Mutant CRC
(MedPage Today) -- Adagrasib (Krazati) demonstrated antitumor activity in heavily pretreated patients with KRAS G12C-mutated, metastatic colorectal cancer (CRC), according to phase I/II study results.
Monotherapy with the oral KRAS inhibitor led... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - December 21, 2022 Category: Gastroenterology Source Type: news
Science ’s 2022 Breakthrough of the Year: A telescope’s golden eye sees the universe anew
html { scroll-behavior: smooth; } .news-article-content--featured>.bodySection>.mb-2x:not(:first-of-type) { display: none; } h3 { scroll-margin-top: 5rem; } .parent-section h3, .subsection h3 { font-size: 1.375rem; line-height: 1.875rem; } .news-article-content-footer h2 { display: none; } .toc img { padding-bottom: 16px; transition: opacity .25s; } .toc img:hover { opacity: 60%; } .toc .image-grid img { padding-bottom: 16px; padding-top: 16px; } .image-grid .news-article__figure__image__wrapper:before, .image-grid .news-article__figure__image__wrapper:after { display: none; } .news-article...
Source: ScienceNOW - December 15, 2022 Category: Science Source Type: news
New Oral SERD Elacestrant -- for Which Breast Cancer Patients? New Oral SERD Elacestrant -- for Which Breast Cancer Patients?
New data from the pivotal trial elacestrant in patients with ER+/HER2- metastatic breast cancer show subgroups that get the greatest progression-free survival benefit.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 14, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Oral SERD Camizestrant Prolongs PFS vs Fulvestrant in Breast Cancer Oral SERD Camizestrant Prolongs PFS vs Fulvestrant in Breast Cancer
"The results of SERENA-2 support further development of camizestrant in ER-positive breast cancer."MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 13, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Roche presents new data demonstrating the potential benefit of glofitamab and Lunsumio as fixed-duration, off-the-shelf treatment options for lymphoma
Data showcase the potential ofglofitamab andLunsumio to address diverse patient needsData presented at ASH 2022 andsimultaneouslypublished in theNew England Journal of Medicine showed thatglofitamab, given as a fixed course, induced early and durable responses in people with heavily pre-treated large B-cell lymphoma1,227-month follow-up data showedLunsumio continued to induce high and durable responses in people with relapsed or refractory follicular lymphoma, with 60% experiencing a complete response3Basel, 12 December 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that updated clinical data for its CD20xCD3 T-...
Source: Roche Investor Update - December 12, 2022 Category: Pharmaceuticals Source Type: news
Roche presents new data demonstrating the potential benefit of glofitamab and Lunsumio as fixed-duration, off-the-shelf treatment options for lymphoma
Data showcase the potential ofglofitamab andLunsumio to address diverse patient needsData presented at ASH 2022 andsimultaneouslypublished in theNew England Journal of Medicine showed thatglofitamab, given as a fixed course, induced early and durable responses in people with heavily pre-treated large B-cell lymphoma1,227-month follow-up data showedLunsumio continued to induce high and durable responses in people with relapsed or refractory follicular lymphoma, with 60% experiencing a complete response3Basel, 12 December 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that updated clinical data for its CD20xCD3 T-...
Source: Roche Media News - December 12, 2022 Category: Pharmaceuticals Source Type: news
